• Highest clinically proven bioavailability on the market
• At least 100 TIMES more bioavailable than standard curcumin extracts
• Each 133mg capsule is EQUIVALENT TO OVER 13g of a standard curcumin extract
• Studied in fragile populations
Serving Size: 1 Capsule
Longvida® Optimized Curcumin (from Curcuma longa root 25:1) … 133.3 mg
Non-medicinal ingredients: ascorbyl palmitate, soy lecithin (non-GMO), maltodextrin, microcrystalline cellulose, silicon dioxide, stearic acid. Capsule: hypromellose.
AOR Guarantees: that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, eggs, dairy, fish, shellfish or any animal byproduct.
Source: Longvida® Optimized Curcumin from turmeric root
Pro Curcumin provides Longvida® Optimized Curcumin. Curcuma longa is traditionally used in Herbal medicine to as an anti-inflammatory to help relieve joint pain and provides antioxidants for the maintenance of good health.
Mechanism of Action
Solid Lipid Particle (SLPTM) technology makes the curcumin particles gastric resistant, hides it from phase II detoxification and enhances their absorption through the gut and through cell membranes; shown to be over 100x more bioavailable than standard curcumin
Prevents phosphorylation of IkB, which inhibits NF-kB activation and therefore proinflammatory cytokine production (ie. ILs, TNF- α )
Inhibits PGE2, 5-LOX, 12-LOX, COX-2
May enhance activity of glutathione-S-transferase, a detoxifying enzyme
Mechanisms related to A β :
May enhance binding of amyloid- β to type I macrophages
Decreases IL- β , which reduces deposition of A β
Protects cerebral endothelial cells against A β -induced mitochondrial damage by inhibiting AP-1 (activator protein 1)
May help chelate copper and iron which reduces the toxicity of A β
May suppress JNK activation which would reduce A β and glutamate-induced neurotoxicity
May inhibit A β -heme peroxidase which causes oxidative damage in the brain
Longvida® curcumin lowered plasma beta amyloid protein, plasma TG, plasma sICAM readings, salivary amylase, plasma alanine amino transferase activities
Longvida® curcumin increased salivary radical scavenging capacities, plasma catalase activities, plasma myeloperoxidase without increased c-reactive protein levels, plasma nitric oxide
Research evidence for the safety and superiority of curcumin treatment in patients with active RA
Research on the effects of curcumin in cancer and Alzheimer's disease is booming, however most studies to date have not used a highly bioavailable curcumin and have therefore found poor solubility and low results
Curcumin is beginning to be considered a general anti-inflammatory for any inflammatory disease (ie. diabetes, IBD, Crohn's, atherosclerosis, etc.)
Current Use in Clinical Practice
Powerful antioxidant protection
Joint pain & inflammation
Relieves pain and inflammation
90 Vegi-Caps, 133.3 mg per capsule
Suggested Use: Take 1 to 2 capsules daily, or as directed by a qualified health care practitioner.
Potential side effects/Safety
Caution: Consult a health care practitioner prior to use if you are pregnant, taking antiplatelet medication or blood thinners, if you have gallstones, a bile duct obstruction, stomach ulcers or excess stomach acid or if symptoms persist or worsen.
Begum et al. Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease. J Pharmacol Exp Ther. 2008 Jul;326(1):196-208.
Chandran B, Goel A.A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012 Nov;26(11):1719-25.
Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012 Nov;35(11):2121-7.
Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG. Chronic safety of Longvida. Food Chem Toxicol. 2011 May 6.
Disilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012 Sep 26;11:79.
Frautschy, SA. Bioavailability, brain concentrations, activity and dose-response of Longvida® SLCP. 38th Annual Meeting of the Society of Neuroscience , Washington DC, November 15, 2008.
Frautschy, SA et al. Omega 3 DHA and a bioavailable curcumin formulation synergize for Alzheimer prevention. 39th Annual Meeting of the Society of Neuroscience , Chicago, IL October 2009.
Frautschy, SA et al. Efficacy of Longvida® in relation to systemic availability in the brain. 39th Annual Meeting of the Society of Neuroscience , Chicago, IL October 2009.
Gota et al. afety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Ag Food Chem 2010 58(4): 2095-2099.
Hamaguchi T et al. REVIEW: Curcumin and Alzheimer's Disease. CBS Neuroscience and Therapeutics. 2010; 16(5): 285-297.
Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005 Nov;50(11):2191-3.
Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009 Jun;14(2):141-53.
Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys. 2012 Oct;49(5):306-15.
Maradana MR, Thomas R, O'Sullivan BJ. Targeted delivery of curcumin for treating type 2 diabetes. Mol Nutr Food Res. 2013 Mar 14.
Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, Zheng X, Espinosa-Jeffrey A, Mahanian M, Liu PT, Hewison M, Mizwickie M, Cashman J, Fiala M. 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2009;17(3):703-17.
Ray B, Lahiri DK. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol. 2009 Aug;9(4):434-44.
Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. Biofactors. 2013 Jan-Feb;39(1):69-77.
Yallapu MM, Ebeling MC, Jaggi M, Chauhan SC. Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab. 2013 May 1;14(4):504-15.
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.healthydigestionclinic.com © 2015 NDAssist Inc. and/or its affiliates. All rights reserved.